A model-based approach for simulating adaptive clinical studies with surrogate endpoints used for interim decision-making
In clinical trials, when exploring multiple dose groups to establish efficacy and safety on one or more selected doses, adaptive designs with interim dose selection are often used for dropping less effective dose groups. When it takes a long time to observe primary outcomes, utilizing information on...
Main Authors: | Xiaotian Chen, Alan Hartford, Jun Zhao |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2020-06-01
|
Series: | Contemporary Clinical Trials Communications |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2451865420300466 |
Similar Items
-
Value of Adaptive Trials and Surrogate Endpoints for Clinical Decision-Making in Rare Cancers
by: Andriy Krendyukov, et al.
Published: (2021-03-01) -
Response Adaptive Randomization using Surrogate and Primary Endpoints
by: Wang, Hui
Published: (2016) -
Surrogate endpoint evaluation using data from one large global randomized controlled trial
by: Milan Geybels, et al.
Published: (2021-05-01) -
Searching for potential surrogate endpoints of overall survival in clinical trials for patients with prostate cancer
by: Hideki Maeda, et al.
Published: (2021-06-01) -
Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic colorectal cancer
by: Cicero G, et al.
Published: (2018-05-01)